CRDF

Cardiff is a clinical-stage company whose entire value rests on onvansertib, an oral PLK1 inhibitor still in mid-stage trials (RAS-mutated mCRC plus investigator-initiated mPDAC, SCLC, mTNBC, CMML). The $593K of FY2025 'revenue' is royalty income unrelated to the drug, so the P/S of 146x and the -7,732% net margin are noise — there is no commercial business to value yet. Management says so plainly: 'We are a clinical stage company and may never earn a profit' and 'We will need to raise substantial additional capital to develop and commercialize onvansertib.' That is going-concern language, and it is the center of the case.

The balance sheet is deteriorating fast. Cash fell 66% to $17.5M, total assets dropped 36% to $61.9M, and equity fell 45% to $45.4M against a $430M accumulated deficit that grew ~12% in the year. Operating cash burn was -$37.9M. Current assets of $60.1M (the gap above cash is short-term investments) buy perhaps ~1.5 years of runway, but a raise is a question of when, not if — and with the stock at $1.27 and a $86.8M cap, that raise is almost certainly dilutive equity on top of the 2.8% share growth already booked. Five straight years of widening losses (-$28M → -$46M) with revenue stuck under $0.7M show this is a cash-consumption story, not a growth story.